Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 4/20 | 0.48 |
| ▸ | NAMPT | P43490 | 7/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10277222 | 1.00 | ATR (0.48) | ATRNAMPTLRRK2PIK3CDPIK3CB | |
| SCHEMBL17032789 | 0.86 | NAMPT (0.48) | ATRNAMPT | |
| SCHEMBL16070038 | 0.84 | ATR (0.65) | ATRPRKDCATMMTOR | |
| SCHEMBL10310892 | 0.82 | ATR (0.46) | ATRLRRK2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2640812 | 0.81 | ATR (0.54) | ATRPRKDCATMMTOR | |
| SCHEMBL16069984 | 0.80 | ATR (0.57) | ATRPRKDCATMMTOR | |
| SCHEMBL18177405 | 0.79 | ATR (0.47) | ATRNAMPTPRKDCATM | |
| SCHEMBL16070009 | 0.79 | ATR (0.63) | ATRPRKDCATMMTOR | |
| SCHEMBL2485624 | 0.77 | ATR (0.60) | ATRPRKDCATMMTOR | |
| SCHEMBL16975604 | 0.76 | LRRK2 (0.45) | ATRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150239874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239874-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K20 | ATR 1/4885NAMPT 1671/4885LRRK2 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.